Sanofi

Bayer Healthcare LLC

Joerg Birkenfeld

Jan Tebbe

Zhuozhi Wang

Christian Votsmeier

Nina Wobst

Junliang Pan

Susanne Steinig

Peter Scholz

Gary J Nabel

Joerg Thomas Regula

Huawei Qiu

Ercole Rao

Béatrice Cameron

Christian Beil

Tarik Dabdoubi

Catherine Prades

Cendrine Lemoine

Ling Xu

Zhi-Yong Yang

Jochen Beninga

Lan Wu

Edward Seung

Joanna Grudzinska

Simone Brueckner

Zhen Xing

Ronnie Rong Wei

Joanna Grudzinska-Goebel

Wulf Dirk Leuschner

Marion Schneider

Simone Brückner

Werner Dittrich, I

Ronnie Wei

Provided herein are trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.

Trispecific binding proteins, methods, and uses thereof

The present invention relates to a method for producing a fusion polynucleotide encoding a polypeptide of interest. The method comprises the steps of providing a first polynucleotide and a second polynucleotide, and contacting said first polynucleotide and second polynucleotide with a type IIs restriction endonuclease and a ligase under conditions that allow for the cleavage of the first polynucleotide and second polynucleotide by said type IIs restriction endonuclease and the ligation of the resulting cleavage products, thereby producing the fusion polynucleotide encoding the polypeptide of interest. The first polynucleotide comprises the 5' portion of an intron, and the second polynucleotide comprises the 3&#x2032; portion of an intron. Further envisaged by the present invention is a polynucleotide encoding a polypeptide of interest, which, when transcribed in a eukaryotic host cell, is transcribed into a transcript comprising at least five introns which are heterologous to said polynucleotide.

Intron-based universal cloning methods and compositions

Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.

Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)

Growing community of inventors

Frankfurt am Main, Germany

Joerg Birkenfeld